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a b s t r a c t
There is an increasing need to measure treatment-related side effects in normal tissues following cancer
therapy. The ALERT-B (Assessment of Late Effects of RadioTherapy - Bowel) questionnaire is a screening
tool that is composed of four items related specifically to bowel symptoms. Those patients that respond
with a ‘‘yes” to any of these items are referred on to gastroenterologist in order to improve the long-term
consequences of these side effects of radiological treatment. Here we wish to test the ability of this ques-
tionnaire to identify these subsequent gastroenterological complications by tracking prostate cancer
patients that were positive with respect to ALERT-B. We also carry out receiver-operator curve (ROC)
analysis for baseline data for an overall ALERT-B questionnaire score with respect to subscale data for
the Gastrointestinal Symptom Rating Scale (GSRS) and the Expanded Prostate Cancer Index Composite
(EPIC-26) questionnaire. 84.4% and 95.7% of patients identified by the ALERT-B questionnaire demon-
strated complications diagnosed at 6 and 12 months post-treatment, respectively. ROC curve analysis
of baseline data showed that ALERT-B detected clinically relevant levels of side effects established at
baseline by the GSRS diarrhoea subscale (AUC = 0.867, 95% CI = 0.795 to 0.926) and at the minimally
important level of side effects for the EPIC bowel subscale (AUC = 0.765, 95% CI = 0.617 to 0.913).
These results show that ALERT-B provides a simple and effective screening tool for identifying gastroen-
terological complications after treatment for prostate cancer.
 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Prostate cancer is the one of the most common cancers in men
in the UK. There were 47,151 new cases of prostate cancer identi-
fied in the UK in 2015 [1] and 11,631 deaths attributed to the dis-
ease in 2016 [1]. Almost 95% of men diagnosed with prostate
cancer in England and Wales survive for one year or more and
84% survive ten years or more [1]. Much evidence exists that
relates to both the short- and long-term effects of standard thera-
pies such as prostatectomy and radiotherapy [2]. Radiotherapy for
men with prostate cancer is administered via external beam
radiotherapy (EBRT), low-dose-rate (LDR) brachytherapy or high-
dose-rate (HDR) brachytherapy [3]. These treatments can be
administered singly or together, perhaps also with hormone ther-
apy or surgery. 17,000 cancer patients in the UK were estimated
to receive pelvic radiotherapy each year [4]. The measurement
(and reporting) of treatment-related side effects in normal tissues
following cancer therapy is an important topic generally [5–8].
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Specifically relating to prostate cancer, it has been reported that
90% of patients [9,10] develop a permanent change in their bowel
habit and 50% experience reduced quality of life [9–11], and fur-
thermore 20% to 40% of these patients rate the effect on quality
of life as moderate or severe [12]. Although caution needs to be
used in terms of generalizability, this also indicates that such side
effects can be both common and severe in some patient groups.
Despite the significant impact that these bowel habit changes
can have on quality of life, only one in five patients who develop
gastrointestinal (GI) symptoms after pelvic radiotherapy are
referred to a gastroenterologist [12]. A discussion of the possible
reasons for this is given in a protocol paper for the EAGLE study
[13], which aims to implement an innovative service to improve
the care offered to men diagnosed with prostate cancer. The Opti-
mising Radiotherapy Bowel Injury Therapy (ORBIT) trial [14]
demonstrated that these symptoms can be diagnosed accurately
and that they can be treated effectively at very modest cost com-
pared to the cost of the cancer treatment itself, and that this
approach leads to improvements in pelvic radiation-induced GI
symptoms as measured by Inflammatory Bowel Disease
Questionnaire-Bowel (IBDQ-B) scores. The ORBIT trial showed that
patients who were offered targeted interventions from clinicians
who followed a detailed algorithm had better improvements in
GI symptoms when compared to patients who were given usual
care [14], thus indicating the potential benefits to both patients
and clinicians. The EAGLE study uses the ALERT-B (Assessment of
Late Effects of RadioTherapy - Bowel) questionnaire [15,16], which
is composed of four items that require a ‘‘no” or ‘‘yes” response,
namely: 1) get up at night to poo; 2) accidents, such as soiling or
wet wind; 3) blood from your bottom; and, 4) bowel or tummy
problems affecting your daily life. The questionnaire is presented
in Appendix A. Patients who reply ‘‘yes” to any of the questions
are then referred on to a gastroenterologist. A literature review
and expert consensus meeting [15] identified these four items for
ALERT-B. ALERT-B was face tested for its usability and acceptability
using cognitive interviews with 12 patients experiencing late gas-
trointestinal symptoms after pelvic radiotherapy in order to iden-
tify potential problems with the ALERT-B screening tool before its
use in larger studies or in clinical practice. Cronbach’s a was found
[15] to be 0.61 for ALERT-B. This is slightly lower than the generally
accepted cut-off for ‘adequate’ given by a value of a 0.7. (Cron-
bach’s a is strongly affected by the number of items included in
the calculation, with higher numbers of items tending to increase
the value of a). Furthermore, item-scale correlations were high,
r > 0.6, which indicated again that ALERT-B is internally consistent.
Note that exploratory factor analysis was also carried out success-
fully [15]. In summary, these results indicated moderate to good
levels of internal reliability for the ALERT-B screening tool.
A 2013 systematic review [16] details results for 29 different
questionnaires that measure (self-reported) symptoms in localized
prostate cancer. ‘‘Psychometric” analyses such as Cronbach’s a and
exploratory factor analysis (etc.) were seen to be commonmethods
of validation in this review [16], although the authors found that
only seven such questionnaires were acceptable in terms of ‘‘broad
domain coverage, ability to differentiate objective and subjective
experience, good internal consistency and validation in at least
two populations and/or having achieved two types of validations.”
Furthermore, it was noticeable that only two studies in this review
[17,18] examined measures for their sensitivity (proportion of
patients that truly are positive and that are classified as correctly
as positive), specificity (proportion of patients that truly are nega-
tive and that are classified as correctly as negative), positive pre-
dictive value (PPV; proportion of positive predictions that are
correct), and/or negative predictive value (NPV; proportion of neg-
ative predictions that are correct). Despite this general lack of evi-
dence, such information is extremely important in terms of the
clinical validation of these questionnaires. Here we present results
for clinical diagnoses at 6 and 12 months for those patients that
were initially tested as positive via the ALERT-B questionnaire at
baseline. We also carry out receiver operator characteristic (ROC)
curve analysis on baseline data for the ALERT-B questionnaire by
using the Gastrointestinal Symptom Rating Scale (GSRS) question-
naire [19] subscale data and (separately) the (EPIC) questionnaire
(also collected at baseline) as proxies for ‘‘ground truth” data. GSRS
is a validated questionnaire for patients with general gastrointesti-
nal complaints [19–22]. Cronbach’s a for the GSRS questionnaire
ranges from 0.60 to 0.85 in patients with duodenal ulcer and from
0.61 to 0.83 in patients with gastro-oesophageal reflux disease
[19–21]. The GSRS has been used in many areas of gastrointestinal
research [19–25] and it been used to assess cancer patients with
both gastrointestinal and extra-gastrointestinal cancers [26–28].
The GSRS measures 15 gastrointestinal symptoms using a four-
point scale. It assesses five subscales: reflux syndrome (heartburn
and acid regurgitation); acute pain syndrome (abdominal pain,
hunger pains and nausea); indigestion syndrome (borborygmi,
abdominal distension, eructation and increased flatus); diarrhoea
syndrome (diarrhoea, loose stools and urgent need to defecate);
constipation syndrome (constipation, hard stools and feeling of
incomplete evacuation). A subscale score of zero indicates the
symptom is absent, whereas a score of three [23] indicates that
the patient experiences great social and activity-related impair-
ment as a result of negative physiologic symptoms. The original
50-item EPIC questionnaire covered urinary incontinence, irrita-
tion/obstruction items, bowel, sexual and hormonal domains, each
with function and bother subscales [29]. A shorter 26 item version
of EPIC was designed and validated [30]. EPIC-26 has shown satis-
factory test-retest reliability and internal consistency for the uri-
nary, bowel, sexual, and hormonal subscales [30]. All EPIC
subscale scores are transferred linearly onto a 0–100 scale as per
the EPIC scoring manual [31], where a higher score indicates better
function or reduced ‘‘bother”. Our aim is to show that the ALERT-B
provides a simple and effective method of detecting gastroentero-
logical late effects after radiotherapy for prostate cancer.
2. Materials and methods
Ethical approval for this study was given by the North Wales
Research Ethics Committee (REC) (Central & East) Proportionate
Review Sub-Committee (reference 13/WA/0243) and the study
was sponsored by Cardiff University (SPON1238-14). Patients were
recruited from three centres in the United Kingdom, namely, Car-
diff (Clinical Nurse Specialist (CNS) led), Sheffield (physician led),
and Brighton (CNS led). Initially, those patients who attended urol-
ogy/oncology follow-up clinics after receiving radiotherapy treat-
ment for prostate cancer generally within 3 months previously
(see Table 1) were asked to consent to the registration phase by
a trained health care professional working at the oncology clinic.
Those patients who consented then completed the ALERT-B tool,
thus also establishing a baseline for the study. Patients were
excluded thereafter if they met one or more of the following crite-
ria: any factor that affects their ability to communicate their
wishes; an inability to comprehend what is being asked of them;
a lack of capacity to consent; or, cancer recurrence. Definitive diag-
noses by the clinical management team were found at 6 months
and 12 months only for patients that were ‘‘positive” according
to ALERT-B at baseline, and so we can find a form of PPV only. (Cau-
tion should be exercised here though due to missing data at 6 and
12 months). The GSRS and ALERT-B questionnaires were com-
pleted by patients at baseline and subscale scores for the GSRS
were found as per the GSRS scoring manual. In order to obtain
measures of sensitivity and specificity, we use subscales for the
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GSRS questionnaire as proxies for the ‘‘ground truth” at baseline.
An overall ALERT-B score was found for each patient by adding
together the scores for the 4 individual items (where 0 = no and
1 = yes). Cut-offs for the GSRS subscale scores (in the range 1 to
7) of any value greater than 1 (i.e., any complications/symptoms
at all no matter how small) and separately any score greater than
or equal to 3 (i.e., a ‘‘clinically important” level [23]) again in order
to provide proxies for ‘‘ground truth” positives or negatives for all
subscales (pain, reflux, diarrhoea, indigestion, constipation) inde-
pendently. The cut-off for the minimally important difference for
the EPIC questionnaire subscale data is given by 5% [32,33], and
so the minimum level of clinically important effects is taken to
be 95 for the EPIC subscales. ROC curves were then found for the
ALERT-B data against these proxies. All statistical calculations were
carried out using SPSS V23. (More details relating to ‘‘materials and
methods” for this study have previously been published [13]).
3. Results
339 patients were screened initially, and 91 answered ‘‘yes” to
any of the four items in the ALERT-B questionnaire. Of these 339
patients, 314 also completed the GSRS questionnaire at baseline.
The median age at screening was 68.3 years (approximate range:
53 to >86). These patients were referred to a gastroenterologist,
of whom 58 patients accepted this referral. Patient and treatment
characteristics at baseline are shown in Table 1. 56% of these
patients at baseline were recruited in Cardiff, 39% in Sheffield,
and 5% in Brighton. As part of the EAGLE study, 58 patients were
included overall at baseline, 36 patients at 6 months (±2 months),
and 23 patients at 12 months (±2 months). Of these 58 patients at
baseline, 56 returned EPIC questionnaire data. The large amounts
of missing data at 6 and 12 months compared to baseline pre-
cluded the use of imputation methods. (Note that the main results
of the EAGLE study are not presented here as we wish to focus
purely on the ability of the ALERT-B screening tool to detect gas-
troenterological side effects).
Specific diagnoses collected from 33 patients at 6 months and
23 patients at 12 months and the results are shown in Table 2.
(Note that 3 out of the 36 patients at 6 months did not receive
diagnosis at this time point). At 6 months, 5 patients (15%) were
diagnosed as having no complications, 19 patients (58%) as a single
complication, and 9 (27%) as two complications. At 12 months, 1
patient (4%) was diagnosed as having no complications, 6 patients
(26%) as a single complication, and 8 (35%) as two complications, 6
(26%) as three complications, and 2 (9%) as four complications. The
number of complications rose from a mean of 1.12 per person and
a median of 1 per person at 6 months to a mean of 2.09 per person
and a median of 2 per person at 12 months, which constitutes a
significant increase in the number of complications (Wilcoxon
signed-rank test: z = 3.345, P(2-tailed) < 0.001). However, some
caution should be exercised here due to missing data. One of the
33 patients at 6 months responded ‘‘no” to all ALERT-B items at
baseline, although this patient did also demonstrate some
symptoms at this point and so they were referred on to the
Table 1
Patient and treatment characteristics at baseline. (Age was collected for 236 subjects and all other fields for those subjects that scored positive via ALERT-B. Note also that there
was some missing data).
Age (years) Mean Standard deviation Median
72.9 6.6 68.3
Time to baseline from radiotherapy n Percentage (%)
0 to 3 months 50 87.7
3 to 9 months 3 5.3
9 to 15 months 3 5.3
Total 57 100
Treatment EBRT alone 56 98.3
EBRT + Brachytherapy 1 1.7
Total 57 100
Dose fractionation schedules 2-Gy equivalent dose (a/b = 3 Gy)1 n Percentage (%)
46 Gy/23 fractions (with HDR boost) 46.00 Gy 2 3.5
52.5 Gy/20 fractions 59.06 Gy 2 3.5
55 Gy/20 fractions 63.25 Gy 1 1.8
57 Gy/19 fractions 68.40 Gy 1 1.8
60 Gy/60 fractions 48.00 Gy 1 1.8
60 Gy/20 fractions 72.00 Gy 14 24.6
70 Gy/20 fractions 91.00 Gy 1 1.8
70 Gy/37 fractions 68.49 Gy 10 17.5
74 Gy/37 fractions 74.00 Gy 23 40.4
74 Gy/5 fractions 263.44 Gy 1 1.8
74 Gy/25 fractions 88.21 Gy 1 1.8
Total 57 100
Androgen deprivation therapy n Percentage (%)
Yes 39 68.4
No 18 31.6
Total 57 100
Staging T1 6 11.1
T2 27 50.0
T3 21 38.9
Total 54 100
Gleason Grade 1 1 1.9
2 36 66.7
3 15 27.8
4 or 5 2 3.7
Total 54 100
1 Dose per fraction (DPF) = total dose/number of fractions; effective dose = total dose  {1 + DPF/(a/b)} = total dose  {1 + DPF/3}; equivalent dose = effective dose/{1 + 2/(a/
b)} = 3  effective dose/5.
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gastroenterology team. Hence, proportions for specific diagnoses
are shown in Table 3 for 32 patients at 6 months and all 23 patients
at 12 months that received a positive score from the ALERT-B ques-
tionnaire (i.e., at least one ‘‘yes”). Radiation proctopathy and ‘‘diag-
noses of special interest” increased from 6 to 12 months, although
these increases were not significant (P > 0.05). There was a signif-
icant increase (P = 0.016) in radiation proctopathy and a diagnosis
of at least one other complication or symptom going from 6months
to 12 months. Finally, results for the proportion relating to ‘‘at least
one complication” (arguably a form of PPV) increased from 84.4%
at 6 months to 95.7% at 12 months, although this was not signifi-
cant (P > 0.05). 339 patients completed the ALERT-B questionnaire
at baseline and 315 patients also returned GSRS data at this point.
ROC curves for this data are presented in Fig. 1. These results sug-
gest that the ALERT-B questionnaire performs better for higher cut-
off (GSRS subscale score  3) rather than the lower cut-off than
compared (GSRS subscale score > 1). Indeed, ALERT-B would be
expected to capture higher levels of complications compared to
any symptoms at all (no matter how small). The highest areas
under the curve (AUC) and associated 95% confidence intervals
for the AUC were for the GSRS diarrhoea subscale. This reflects
the focus of the ALERT-B tool, which addresses bowel symptoms
only. Note that AUC = 0.79 (95% CI = 0.738 to 0.843) for diarrhoea
subscale scores > 1 and AUC = 0.867 (95% CI = 0.795 to 0.926) for
diarrhoea subscale scores  3. These results for the bowel subscale
are significantly different to the ‘‘reference” line (i.e., the 95% CI
does not include the critical value of AUC = 0.5). The highest AUC
for ALERT-B compared to EPIC questionnaire data was for the
bowel subscale. As expected, all of the other subscales (urinary
incontinence, urinary irritation/obstruction, sexual, and hormonal)
had lower values for the AUCs, which were not significantly differ-
ent to the critical value of AUC = 0.5. Note also that these calcula-
tions were hampered by a very small sample size (n = 56) which
strongly affects the reliability of the results for these ROC curves,
and so these results are not presented here for these specific EPIC
subscales. Despite this limitation however, an of AUC = 0.765 (95%
CI = 0.617 to 0.913) was obtained for a cut-off of less than or equal
to 95 (i.e., the minimum level of clinically important effects
[32,33]) for the EPIC bowel subscale score, which is another
encouraging result.
Table 2
Number and percentages of specific diagnoses collected from 33 patients at 6 months and 23 patients at 12 months.
Diagnosis 6 months 12 months
n Percentage (%) n Percentage (%)
Diverticular disease 9 27 4 17
Pelvic floor/sphincter weakness 0 0 6 26
Colonic adenoma 6 18 5 22
Lactose/fructose intolerance 0 0 4 (2/2) 17
Bile salt malabsorption 4 12 4 17
Dietary issues 3 9 4 17
Small intestinal bacterial overgrowth 2 6 3 13
‘‘Other” such as vitamin B12 deficiencies, alcohol excess etc. 5 15 6 26
Table 3
Number (percentages in brackets) of patients with specific diagnoses from 32 patients at 6 months and 23 patients at 12 months that received a positive score from the ALERT-B
questionnaire ‘‘diagnoses of special interest” = a diagnosis of any of the following: bile salt malabsorption, small intestinal bacterial overgrowth, lactose intolerance, vitamin b12
insufficiency, floor/sphincter.
At least one complication
(P = 0.5)
Radiation proctopathy
(P = 0.125)
Radiation proctopathy & at least one other
(P = 0.016)
‘‘Diagnoses of special interest”
(P = 0.063)
6 months 27 (84.4%) 8 (25.0%) 4 (12.5%) 7 (21.9%)
12 months 22 (95.7%) 12 (52.2%) 11 (47.8%) 12 (52.2%)
Fig. 1. Receiver operator characteristic (ROC) curve using GSRS as a proxy for ground-truth. (Left) ground truth for GSRS subscale scores > 1. (Right) ground truth for GSRS
subscale scores  3.
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4. Discussion
Patient-reported outcome measures of the side effects of cancer
treatment are routinely tested psychometrically by standard meth-
ods such as Cronbach’s alpha and exploratory factor analysis.
Rather less attention has been given to measures of clinical validity
based on some ‘‘ground truth” that has been established, e.g., by
clinical diagnosis. In this instance, 84.4% and 95.7% of those
patients identified as a ‘‘positive” by ALERT-B subsequently went
on to demonstrate clinically diagnosed complications at 6 and
12 months post-treatment, respectively. However, caution must
be exercised in interpreting these results as a PPV owing to the
amount of missing data (43% at 6 months and 60% at 12 months),
which can bias estimates. Nevertheless, it is important to note that
all of the patients identified by ALERT-B are those we would expect
to have gained clinical benefit from the systematic screening for
symptoms. Furthermore, 25% of patients retained at 6 months
and 52% of patients at 12 months identified by ALERT-B had a diag-
nosis of radiation proctopathy; these could have been diagnosed
with direct referral for flexible sigmoidoscopy. 12.5% of patients
retained at 6 months and 47.8% of patients at 12 months identified
by ALERT-B were diagnosed with radiation proctopathy and at
least one other complication or symptom; these patients would
be expected to gain a clinical benefit from systematic algorithmic
management (with subsequent assessment and systematic investi-
gation thereafter) and not ‘‘just” direct referral for flexible sigmoi-
doscopy. Finally, ROC curve analysis suggested that ALERT-B at
baseline performed well in comparison to a ‘‘ground truth” based
on baseline subscale scores for the GSRS diarrhoea and EPIC bowel
subscales (especially) at clinically relevant levels. For GSRS diar-
rhoea subscale scores (3), the AUC was 0.867 (95% CI = 0.795 to
0.926). For EPIC bowel subscale scores (95), the AUC was
AUC = 0.765 (95% CI = 0.617 to 0.913).
5. Conclusion
The ALERT-B questionnaire provides a simple and effective
screening tool for detecting gastroenterological late effects after
radiotherapy for prostate cancer. ALERT-B is an integral part of
the EAGLE study, which aims to implement an innovative service
to improve the care offered to men diagnosed with prostate cancer.
Specifically, patients identified by ALERT-B will be offered targeted
interventions from clinicians via a detailed algorithm, which will
lead to improvements in gastrointestinal symptoms.
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